India’s PharmNXT Biotech targets the global bioprocessing market with cost-effective innovation
As global demand for biologics rises, pharmaceutical manufacturing is undergoing a structural shift. Biologic drugs, including monoclonal antibodies, vaccines, and advanced therapies, are expected to account for nearly 35–40 percent of the global pharmaceuticals market by 2030, according to IQVIA. At the same time, rising costs in the United States and Europe, along with supply disruptions during the COVID-19 pandemic, have accelerated the need for more diversified and resilient manufacturing ecosystems.